Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
about
The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase IIParathyroid cancerGenetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumorsCdc73 Subunit of Paf1 Complex Contains C-terminal Ras-like Domain That Promotes Association of Paf1 Complex with ChromatinParafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult miceThe parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3.Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.Aberrant WNT/β-catenin signaling in parathyroid carcinoma.CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinomaChallenges and pitfalls in the management of parathyroid carcinoma: 17-year follow-up of a case and review of the literatureParathyroid cancer.Parathyroid carcinoma arising from four-gland hyperplasia.Molecular alterations in sporadic primary hyperparathyroidismDiagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis.Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas.Intrathyroidal parathyroid carcinoma: report of an unusual case and review of the literature.Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery.CDC73 gene mutations in sporadic ossifying fibroma of the jaws.Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessmentCDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.Parathyroid tumors and related disorders.Metastatic parathyroid carcinoma initially misdiagnosed as parathyroid adenoma: the role of parafibromin in increasing diagnostic accuracy.Parathyroid carcinoma: increasing incidence and changing presentation.Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes.Translational research in endocrine surgery.Understanding the genetic basis of parathyroid carcinoma.Molecular profiling in primary hyperparathyroidism.Clinicopathological correlates of hyperparathyroidism.Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms.Update on parathyroid carcinoma.Apoptosis in Primary Hyperparathyroidism.Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.Molecular diagnosis of parathyroid carcinoma: a reality in the near future.Nucleolar localization of parafibromin is mediated by three nucleolar localization signals.Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen.Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin.Immunohistochemical Expression of E-Cadherin in Atypical Parathyroid Adenoma.Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse?Expression of parafibromin in major renal cell tumors.Parafibromin Staining Characteristics in Urothelial Carcinomas and Relationship with Prognostic Parameters.
P2860
Q24304135-FF25CDCC-73C2-4AD4-8DCD-4A84BB794F13Q26796612-D3820026-44F6-4AB7-A4DB-612898D97E63Q27025359-47C2CFB2-AE26-46A1-8E3F-6A3BBBE0BB8AQ27677158-891676D9-1369-4F25-94FD-CF13C86DC425Q28592704-13EFA4AA-32DC-4DF9-91B1-FCBA6B58A593Q33358543-7367B248-0621-45A6-B2FF-2A9C3917B5C2Q33907163-8C112ED2-E5F7-426A-9858-808277285514Q34360642-BA4D57D0-D9EE-40AC-90AD-D4F6A786B6CAQ34396517-1C979226-94BE-4B74-855C-885ECFF27683Q34398386-79E03DB4-F361-4CB0-B5A2-E73A4C13BC4EQ34686824-5C8383DF-7893-4B45-9377-D42D434680FFQ34792877-83A6CF1C-5292-4F61-8778-A715C98BF057Q35910367-A9C9527C-7409-4D1F-9CAC-2CC05CE64A63Q36037109-CD67DC98-3F73-47CA-9D64-06ED49B28769Q36444814-915F2930-3035-4C16-AF69-E858FF6D3347Q37052193-D97D3EEA-B89C-4512-A55A-511F69E5971DQ37274291-CBE984A4-7E29-4BCC-A50C-6D0A31D5D24BQ37278906-D0AE8737-7FF2-467A-9291-2E081C5E328CQ37353629-BA8F6F11-4E09-4D13-A2C3-EE43464F688CQ37358248-76BF2760-34E8-4F40-A800-AF234BF14992Q37860135-96EE3561-BA70-4355-AC1E-209F1C1979F1Q37928742-0D7201F2-5369-443A-B5D4-DF257139A6F0Q37980468-26E92A96-3968-408B-A049-D271535F0315Q38089260-7EDE3E49-604C-4484-AB36-C920C8F8EA4CQ38135137-767E9F82-D360-45BE-95D9-4D7FC38A6D15Q38176824-E9E59912-B825-4639-B576-17E919715708Q38193373-41DBABAF-3F1C-46AD-BF46-9815C7A7FD24Q38545172-289BFCC4-E68B-477A-9091-97E8715A8210Q38777548-C1B560BE-7F69-422F-AABB-1CDD9E81E87AQ38784218-72F0E827-80DF-452E-AB44-F7683442C674Q39211022-FA7BCBF9-817B-49F5-B767-D2462E417E2CQ39412594-083B49BC-F92F-4E4B-B936-ED2A1AE5A193Q39670916-5CEB430B-E98D-4588-AC54-99080C124DE5Q40070522-B6A8BF25-155A-4D2F-87C3-9673EBC42BDDQ40150454-F451E1B1-89BF-4619-B4CD-D1ACB3E2BE30Q40382150-144F6A85-BC03-4ED3-B7B0-5A44D4EB1B4FQ40758523-51D52A24-5306-4BA0-BCBC-344AD6DEA71CQ41296038-3CB16FFD-3C9F-49EB-B25A-15BC69CF4B31Q41766499-39C006AD-48C9-41E8-BCFA-B2999F1AAD59Q41775003-B9D54646-E12E-4F02-94F7-2FF025270402
P2860
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Loss of parafibromin immunorea ...... ture of parathyroid carcinoma.
@en
type
label
Loss of parafibromin immunorea ...... ture of parathyroid carcinoma.
@en
prefLabel
Loss of parafibromin immunorea ...... ture of parathyroid carcinoma.
@en
P2093
P1476
Loss of parafibromin immunorea ...... ture of parathyroid carcinoma.
@en
P2093
Carl Morrison
Carola J Haven
Chun Zhang
Eeva Korpi-Hyovalti
Hans Morreau
James Resau
John R Burgess
Khee Chee Soo
Maria S Tretiakova
P304
P356
10.1158/1078-0432.CCR-04-0493
P407
P50
P577
2004-10-01T00:00:00Z